Key clinical point: Final results from the ELOQUENT-2 trial suggest that adding elotuzumab to lenalidomide plus dexamethasone can prolong overall survival in patients with relapsed/refractory multiple myeloma.
Major finding: At a minimum follow-up of 6 years, elotuzumab plus lenalidomide/dexamethasone reduced the risk of death by 18% and prolonged the median overall survival by 8.7 months when compared to treatment with lenalidomide/dexamethasone alone.
Study details: A phase 3 trial of 646 patients with relapsed/refractory multiple myeloma.
Disclosures: The trial was sponsored by Bristol-Myers Squibb in collaboration with AbbVie. The speaker reported relationships with Bristol-Myers Squibb, Amgen, Celgene, Janssen, and Takeda.
Dimopoulos MA et al. IMW 2019, Abstract OAB-021.